BRPI0412252A - derivados de insulina de longa duração e métodos dos mesmos - Google Patents

derivados de insulina de longa duração e métodos dos mesmos

Info

Publication number
BRPI0412252A
BRPI0412252A BRPI0412252-6A BRPI0412252A BRPI0412252A BR PI0412252 A BRPI0412252 A BR PI0412252A BR PI0412252 A BRPI0412252 A BR PI0412252A BR PI0412252 A BRPI0412252 A BR PI0412252A
Authority
BR
Brazil
Prior art keywords
methods
long
insulin derivatives
insulin molecule
term insulin
Prior art date
Application number
BRPI0412252-6A
Other languages
English (en)
Inventor
Dominique P Bridon
Jean-Paul Castaigne
Xicai Huang
Roger Leger
Martin Robitaille
Original Assignee
Conjuchem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34118817&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0412252(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Conjuchem Inc filed Critical Conjuchem Inc
Publication of BRPI0412252A publication Critical patent/BRPI0412252A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

"DERIVADOS DE INSULINA DE LONGA DURAçãO E MéTODOS DOS MESMOS". A presente invenção refere-se a um derivado de insulina, que compreende uma molécula de insulina e um grupo reativo para covalentemente ligar um componente sangüineo, no qual preferencialmente a molécula de insulina é molécula de insulina humana natural e o grupo reativo é acoplado a um aminoácido da molécula de insulina sob uma posição selecionada das posições Gly A1, Phe B1 e Lys B29.
BRPI0412252-6A 2003-07-25 2004-07-26 derivados de insulina de longa duração e métodos dos mesmos BRPI0412252A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49011003P 2003-07-25 2003-07-25
US55658504P 2004-03-25 2004-03-25
PCT/CA2004/001409 WO2005012346A1 (en) 2003-07-25 2004-07-26 Long lasting insulin derivatives and methods thereof

Publications (1)

Publication Number Publication Date
BRPI0412252A true BRPI0412252A (pt) 2006-09-19

Family

ID=34118817

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0412252-6A BRPI0412252A (pt) 2003-07-25 2004-07-26 derivados de insulina de longa duração e métodos dos mesmos

Country Status (16)

Country Link
US (1) US20060241019A1 (pt)
EP (2) EP2085406A1 (pt)
JP (2) JP2007520441A (pt)
AT (1) ATE433994T1 (pt)
AU (2) AU2004261319B2 (pt)
BR (1) BRPI0412252A (pt)
CA (1) CA2526957C (pt)
DE (1) DE602004021603D1 (pt)
DK (1) DK1648933T3 (pt)
EA (1) EA008433B1 (pt)
ES (1) ES2328579T3 (pt)
HK (1) HK1091843A1 (pt)
NO (1) NO20060888L (pt)
PL (1) PL1648933T3 (pt)
SI (1) SI1648933T1 (pt)
WO (1) WO2005012346A1 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
CA2363712C (en) * 1999-05-17 2011-05-10 Conjuchem Inc. Long lasting insulinotropic peptides
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
AU2002233089B2 (en) 2001-02-16 2005-12-22 Conjuchem Biotechnologies Inc. Long lasting glucagon-like peptide 2 (GLP-2) for the treatment of gastrointestinal diseases and disorders
TWI376234B (en) 2005-02-01 2012-11-11 Msd Oss Bv Conjugates of a polypeptide and an oligosaccharide
EP1846447B1 (en) 2005-02-02 2013-08-21 Novo Nordisk A/S Insulin derivatives
KR101441444B1 (ko) * 2006-05-09 2014-09-18 노보 노르디스크 에이/에스 인슐린 유도체
MX2009002999A (es) 2006-09-22 2009-04-01 Novo Nordisk As Analogos de insulina resistentes a proteasa.
US7982018B2 (en) 2006-10-16 2011-07-19 Conjuchem, Llc Modified corticotropin releasing factor peptides and uses thereof
JP5496082B2 (ja) 2007-04-30 2014-05-21 ノボ・ノルデイスク・エー／エス タンパク質組成物を乾燥させる方法、乾燥タンパク質組成物、及び乾燥タンパク質を含有する薬学的組成物
WO2009112583A2 (en) 2008-03-14 2009-09-17 Novo Nordisk A/S Protease-stabilized insulin analogues
EP2910570B1 (en) 2008-03-18 2016-10-12 Novo Nordisk A/S Protease stabilized, acylated insulin analogues
WO2009121884A1 (en) 2008-04-01 2009-10-08 Novo Nordisk A/S Insulin albumin conjugates
EP2391217A4 (en) * 2009-01-28 2015-05-20 Smartcells Inc SYNTHETIC CONJUGATES AND USES THEREOF
CA2870313A1 (en) 2012-04-11 2013-10-17 Novo Nordisk A/S Insulin formulations
WO2013172967A1 (en) 2012-05-17 2013-11-21 Extend Biosciences, Inc Carriers for improved drug delivery
WO2015052088A1 (en) 2013-10-07 2015-04-16 Novo Nordisk A/S Novel derivative of an insulin analogue
MA39301A1 (fr) * 2014-01-20 2018-01-31 Hanmi Pharmaceutical Co Ltd Insuline à action prolongée et utilisation associée
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
AR100695A1 (es) 2014-05-30 2016-10-26 Hanmi Pharm Ind Co Ltd Composición para el tratamiento de diabetes mellitus que comprende insulina y un agonista dual glp-1 / glucagón
KR20160001391A (ko) * 2014-06-27 2016-01-06 한미약품 주식회사 신규한 지속형 인슐린 아날로그 결합체 및 이의 용도
JP6946182B2 (ja) 2014-10-22 2021-10-06 エクステンド バイオサイエンシズ インコーポレーテッドＥｘｔｅｎｄ Ｂｉｏｓｃｉｅｎｃｅｓ， Ｉｎｃ 治療用ビタミンｄコンジュゲート
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
CN107531762A (zh) 2015-05-07 2018-01-02 科德克希思公司 青霉素g酰化酶
UY36870A (es) 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd Análogos de insulina novedosos
TWI774694B (zh) 2016-09-23 2022-08-21 南韓商韓美藥品股份有限公司 具有降低對胰島素受體之親和力之胰島素類似物及其用途
PT3554534T (pt) 2016-12-16 2021-11-05 Novo Nordisk As Composições farmacêuticas contendo insulina
WO2018174668A2 (ko) 2017-03-23 2018-09-27 한미약품 주식회사 인슐린 수용체와의 결합력이 감소된 인슐린 아날로그의 결합체 및 이의 용도
CN113855678A (zh) * 2021-09-08 2021-12-31 武汉生命奥义生物科技有限公司 一种用于辅助治疗二型糖尿病的组合物
CN115894719B (zh) * 2022-11-24 2023-10-20 武汉禾元生物科技股份有限公司 一种人血清白蛋白胰岛素偶联物及其制备方法

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3509120A (en) * 1966-12-28 1970-04-28 Squibb & Sons Inc N-terminal mono- and diaminoacyl-insulin
GB1381274A (en) * 1971-01-28 1975-01-22 Nat Res Dev Insulin derivatives
GB1381273A (en) * 1971-01-28 1975-01-22 Nat Res Dev Insulin derivatives
JPS5272284A (en) * 1975-12-12 1977-06-16 Dainippon Pharmaceutical Co Enzymeeimmunoassay reagent
CA1196863A (en) * 1983-06-08 1985-11-19 Mattheus F.A. Goosen Slow release injectable insulin composition
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US5514646A (en) * 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
US5612034A (en) * 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
US5422339A (en) * 1991-03-19 1995-06-06 Joslin Diabetes Center, Inc. Peptides having insulin autoantibody but not insulin receptor binding capacity
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
GB9316895D0 (en) * 1993-08-13 1993-09-29 Guy S And St Thomas Hospitals Hepatoselective insulin analogues
DK72793D0 (da) * 1993-06-21 1993-06-21 Novo Nordisk As Nyt produkt
US6342225B1 (en) * 1993-08-13 2002-01-29 Deutshces Wollforschungsinstitut Pharmaceutical active conjugates
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5693609A (en) * 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
US6251856B1 (en) * 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
DE122010000020I1 (de) * 1996-04-25 2010-07-08 Prosidion Ltd Verfahren zur Senkung des Blutglukosespiegels in Säugern
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US5866538A (en) * 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
DE19726167B4 (de) * 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
US6444641B1 (en) * 1997-10-24 2002-09-03 Eli Lilly Company Fatty acid-acylated insulin analogs
AU1111799A (en) * 1997-10-24 1999-05-17 Eli Lilly And Company Fatty acid-acylated insulin analogs
US20020155994A1 (en) * 1997-10-24 2002-10-24 Svend Havelund Aggregates of human insulin derivatives
ZA989744B (en) * 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
AU766219B2 (en) * 1998-02-02 2003-10-09 1149336 Ontario Inc. Method of regulating glucose metabolism, and reagents related thereto
JP4523153B2 (ja) * 1998-03-19 2010-08-11 ブリストル−マイヤーズ スクイブ カンパニー 易溶性薬物の二層性放出制御送達システムおよび方法
WO1999065941A1 (en) * 1998-06-12 1999-12-23 Kings College London Insulin analogue
US20030190740A1 (en) * 1998-10-13 2003-10-09 The University Of Georgia Research Foundation, Inc Stabilized bioactive peptides and methods of identification, synthesis, and use
JP2002534059A (ja) * 1998-10-13 2002-10-15 ザ ユニバーシティ オブ ジョージア リサーチファウンデーション，インコーポレイティド 安定化された生物活性ペプチドおよび同定、合成および使用方法
US6887470B1 (en) * 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
CA2363712C (en) * 1999-05-17 2011-05-10 Conjuchem Inc. Long lasting insulinotropic peptides
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
EP1623994A3 (en) * 1999-05-17 2008-07-16 ConjuChem Biotechnologies Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6309633B1 (en) * 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
US7169889B1 (en) * 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
US6323311B1 (en) * 1999-09-22 2001-11-27 University Of Utah Research Foundation Synthesis of insulin derivatives
US6586438B2 (en) * 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
EP1299418A1 (en) * 2000-07-10 2003-04-09 BTG INTERNATIONAL LIMITED (Company No. 2664412) Insulin derivatives and synthesis thereof
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
AU2002254940A1 (en) * 2001-03-12 2002-09-24 Novartis Pharma Gmbh Combination of nateglinide or repaglinide with at least one further antidiabetic compound
US6828297B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
UA74912C2 (en) * 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US7166571B2 (en) * 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6913903B2 (en) * 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7196059B2 (en) * 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7312192B2 (en) * 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
AU2003218635A1 (en) * 2002-05-07 2003-11-11 Novo Nordisk A/S Soluble formulations comprising insulin aspart and insulin detemir
WO2003105768A2 (en) * 2002-06-13 2003-12-24 Nobex Corporation Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
US20040138099A1 (en) * 2002-11-29 2004-07-15 Draeger Eberhard Kurt Insulin administration regimens for the treatment of subjects with diabetes
US20050065066A1 (en) * 2002-12-20 2005-03-24 Kaarsholm Niels Christian Stabilised insulin compositions
GB0309154D0 (en) * 2003-01-14 2003-05-28 Aventis Pharma Inc Use of insulin glargine to reduce or prevent cardiovascular events in patients being treated for dysglycemia
DK2599502T3 (en) * 2003-04-11 2017-04-18 Antriabio Inc Process for Preparation of Site-Specific Protein Conjugates
JO2625B1 (en) * 2003-06-24 2011-11-01 ميرك شارب اند دوم كوربوريشن Phosphoric acid salts of dipeptidyl betidase inhibitor 4
MXPA06001283A (es) * 2003-08-05 2006-04-11 Novo Nordisk As Derivados de insulina novedosos.
UA91512C2 (ru) * 2004-07-19 2010-08-10 Биокон Лимитед Коньюгати олигомеров инсулина, их композиция (варианты) и применение
US7718609B2 (en) * 2006-04-12 2010-05-18 Biodel Inc. Rapid acting and long acting insulin combination formulations

Also Published As

Publication number Publication date
SI1648933T1 (sl) 2010-01-29
US20060241019A1 (en) 2006-10-26
EP1648933A1 (en) 2006-04-26
DK1648933T3 (da) 2009-09-07
PL1648933T3 (pl) 2010-01-29
EA008433B1 (ru) 2007-06-29
ES2328579T3 (es) 2009-11-16
DE602004021603D1 (de) 2009-07-30
CA2526957C (en) 2011-07-12
AU2004261319A1 (en) 2005-02-10
JP2012062311A (ja) 2012-03-29
EP1648933A4 (en) 2007-02-28
AU2011201278A1 (en) 2011-04-07
EP2085406A1 (en) 2009-08-05
JP2007520441A (ja) 2007-07-26
AU2004261319B2 (en) 2010-12-23
WO2005012346A1 (en) 2005-02-10
ATE433994T1 (de) 2009-07-15
HK1091843A1 (en) 2007-01-26
EP1648933B1 (en) 2009-06-17
EA200600305A1 (ru) 2006-06-30
NO20060888L (no) 2006-04-25
CA2526957A1 (en) 2005-02-10

Similar Documents

Publication Publication Date Title
BRPI0412252A (pt) derivados de insulina de longa duração e métodos dos mesmos
WO2008047241A3 (en) Modified corticotropin releasing factor peptides and uses thereof
CY1113299T1 (el) Πολυπεπτιδια απροτινινης για τη μεταφορα μιας ενωσης μεσα στον αιματοεγκεφαλικο φραγμο
ATE480568T1 (de) Verbesserte sgp 130fc dimere
NO20015909D0 (no) Anvendelse av (-) (3-trihalometylfenoksy) (4-halofenyl) eddiksyrederivater for behandling av insulinresistens, type 2diabetes, hyperlipidemi og hyperurisemi
CY1113370T1 (el) Ενεσιμο φαρμακευτικο σκευασμα αποτελουμενο απο ενα κυτταροστατικο και μια μηλεϊνιμιδο ομαδα συνδεομενη δια ενος παρεμβαλλομενου μοριου
ATE399185T1 (de) Maleinsäureamid polymerderivate und ihre biokonjugate
WO2003087768A3 (en) Targets for therapeutic intervention identified in the mitochondrial proteome
WO2005012347A3 (en) Novel insulin derivatives
AU2003212961A1 (en) Split tip dialysis catheter
CA2363712A1 (en) Long lasting insulinotropic peptides
WO2004009774A3 (en) Protein conjugates with a water-soluble biocompatible, biogradable polymer
DE602006017667D1 (de) Cysteinhaltiges peptid-tag zur stellenspezifischen konjugation von proteinen
CY1109480T1 (el) ΠΡΩΤΕΪΝΕΣ ΣΥΝΔΕΣΗΣ Gag
WO2006004959A3 (en) Pegylated interferon alpha-1b
WO2007135117A3 (en) Soluble, stable insulin-containing formulations
WO2005116068A8 (fr) Peptides ou conjugues peptidiques derives de la msh et leur utilisation dans le traitement cosmetique de la canitie
EP2017343A3 (en) Protein A based binding domains with desirable activities
WO2008012086A2 (de) Proteinbindende methotrexat-derivate und diese enthaltende arzneimittel
EP1997826A3 (en) Synthetic ligands for immunoglobulins and pharmaceutical compositions containing them
WO2004018502A8 (en) Compounds binding to p-selectin
WO2000070665A3 (en) Long lasting anti-angiogenic peptides
ATE510009T1 (de) Förderung der peroxisomalenkatalasefunktion in zellen
WO2006096079A3 (en) Pharmaceutical composition comprising a biosynthetic analog of human insulin, and its use in the treatment of diabetes mellitus.
WO2010056040A2 (ko) 생체적합성 고분자와 결합한 신규한 에리스로포이에틴 접합체

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: COLABOR GROUP INC. (CA)

Free format text: NOME ALTERADO DE: CONJUCHEM BIOTECHNOLOGIES INC.

B25G Requested change of headquarter approved

Owner name: COLABOR GROUP INC. (CA)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020120015821/RJ DE 27/02/2012.

B25A Requested transfer of rights approved

Owner name: 4523482 CANADA INC. (CA)

Free format text: TRANSFERIDO DE: COLABOR GROUP INC.

B25A Requested transfer of rights approved

Owner name: 4503996 CANADA INC. (CA)

Free format text: TRANSFERIDO POR INCORPORACAO DE: 4523482 CANADA INC.

B25D Requested change of name of applicant approved

Owner name: CONJUCHEM BIOTECHNOLOGIES INC. (CA)

Free format text: NOME ALTERADO DE: 4503996 CANADA INC.

B25A Requested transfer of rights approved

Owner name: CALIFORNIA CAPITAL EQUITY, LLC (US)

Free format text: TRANSFERIDO DE: CONJUCHEM BIOTECHNOLOGIES INC.

B25A Requested transfer of rights approved

Owner name: CONJUCHEM LLC (US)

Free format text: TRANSFERIDO DE: CALIFORNIA CAPITAL EQUITY, LLC

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2259 DE 22/04/2014.